SAN CARLOS, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc., a clinical-stage company specializing in diabetes and obesity medicines, has announced the presentation of new preclinical and clinical data for its investigational oral menin inhibitor, icovamenib. The results were presented at the 85th Scientific Sessions of the American Diabetes Association $(ADA.AU)$ held from June 20-23, 2025, in Chicago. The data, highlighted in one oral presentation and two posters, demonstrate icovamenib's potential in addressing key aspects of type 2 diabetes (T2D) pathophysiology. Notably, icovamenib showed promise in beta cell restoration and exhibited synergy with glucagon-like peptide-1 (GLP-1) receptor agonists, promoting metabolic health and selective fat loss while preserving lean mass. In a rodent model of T2D, the combination of icovamenib and low-dose semaglutide improved glycemic control and body weight reduction compared to semaglutide alone. Furthermore, in the Phase II COVALENT-111 trial, icovamenib led to a 1.0% placebo-adjusted mean HbA1c reduction and a 55% increase in C-peptide in severely insulin-deficient patients by Week 26. These findings have been published in the peer-reviewed journal Diabetes.